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Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy. 
It is a lethal X-linked disorder that affects approximately one in 3500 boys worldwide and is caused 
by mutations in the dystrophin gene. 
To restore functional dystrophin levels in individuals suffering from DMD, muscle stem cell transplant 
therapies are being developed that use healthy donor cells to generate new muscle. Most of these 
transplant approaches use muscle-derived donor cells, as they contain a minor fraction of satellite 
cells that act as myogenic progenitor cells (i.e., muscle stem cells). However, one of the current 
limitations of this approach is that a considerable number of freshly procured donor cells are needed 
for efficient engraftment, particularly as DMD affects a large mass of tissue. Moreover, the 
expansion of muscle-derived donor cells in vitro actually promotes ex vivodifferentiation, thus 
reducing the effective number of myogenic progenitor cells. 
Recently, Drs. Colleen Delaney and Irwin Bernstein of the Clinical Research Division showed that 
culture of human cord blood in the presence of Notch ligand Delta-1
ext
-IgG increased the number of 
hematopoietic stem cells for myeloid repopulation in an immunocompromised murine model 
(NOD/SCID). As activation of Notch signaling is also required for muscle regeneration after injury, 
Dr. Maura Parker, an associate in Clinical Research, conducted a study with members of the Storb 
Lab (Clinical Research), members of the Tapscott Lab (Human Biology Division) and outside 
collaborators to examine whether the culture of canine muscle-derived cells (MDC) with Delta-1
ext
-
IgG improves the yield of myogenic progenitor cells for transplantation. 
The authors found that canine MDC cultured with Delta-1
ext
-IgG for eight days expanded 6.5-20-fold 
prior to transplantation. Although the number of expanded cells did not statistically differ between 
MDC cultured with Delta-1
ext
-IgG and MDC cultured with an irrelevant human IgG, the former did 
exhibit significantly improved myogenic potential compared to the latter. For example, increased 
Pax7 expression was observed in Delta-1
ext
-IgG-expanded MDC by immunohistochemistry, where 
Pax7 is a transcription factor that specifies the muscle stem cell lineage. Delta-1
ext
-IgG-expanded 
MDC also generated significantly more canine dystrophin-positive muscle fibers and more Pax7-
positive cells than control MDC following xenotransplantation into the tibialis anterior muscle of 
NOD/SCID mice hind limbs. Moreover, cells engrafted from Delta-1
ext
-IgG-expanded MDC gave rise 
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to more canine dystrophin-positive muscle fibers following a secondary regeneration event 
induced in situ with barium chloride than MDC expanded with an irrelevant human IgG. 
Although culture with Delta-1
ext
-IgG improved the yield of myogenic progenitor cells from ex 
vivo expansion, xenotransplants performed with 10,000 Delta-1
ext
-IgG-expanded MDC resulted in 
two-fold fewer canine dystrophin-positive muscle fibers than xenotransplants performed with an 
equivalent number of fresh MDC. Nevertheless, because Delta-1
ext
-IgG  expands the total number of 
MDC by up to 20-fold, even if losses in engraftment efficiency compared to fresh MDC are taken into 
account, the effective yield of Delta-1
ext
-IgG-based expansion for transplant purposes remains as 
high as 10-times the starting number of MDC. 
These findings demonstrate that expanding MDC on immobilized Delta-1
ext
-IgG enhances their 
potential to regenerate dystrophin and maintain myogenic progenitor cell populations in recipient 
muscle. Consequently, a Notch activation-based expansion approach may help to improve human 
muscle stem cell transplant therapies in much the same way it has advanced hematopoietic stem 
cell transplants. 
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Prior to transplantation, donor muscle-
derived cells (MDC) were expanded for eight 
days ex vivo with either the Notch ligand 
Delta-1ext-IgG or an irrelevant human IgG. 
The number of total expanded cells did not 
differ between treatment groups; however, 
Delta-1ext-IgG treatment better maintained 
the myogenic potential of MDC. As shown 
above, Delta-1ext-IgG-expanded MDC 
exhibit increased Pax7 expression (green) by 
immunohistochemistry compared to human-
IgG-expanded MDC, where Pax7 specifies 
the muscle stem cell lineage. Cell nuclei are 
stained blue with DAPI. 
